

Association of PCOS with offspring morbidity: a longitudinal cohort study

Shu Qin Wei  ^{1,2}, Marianne Bilodeau-Bertrand², and Nathalie Auger  ^{2,3,4,*}

¹Department of Obstetrics and Gynecology, Sainte-Justine Hospital Research Center, University of Montreal, Montreal, Canada ²Bureau d'information et d'études en santé des populations, Institut national de santé publique du Québec, Montreal, Canada ³Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, Canada ⁴Department of Social and Preventive Medicine, School of Public Health, University of Montreal Hospital Research Centre, University of Montreal, Montreal, Canada

*Correspondence address. 190 Cremazie Blvd E, Montreal, Quebec H2P 1E2, Canada. Tel: +1-514-864-1600, ext: 3717; Fax: +1-514-864-1616; E-mail: nathalie.auger@inspq.qc.ca  <https://orcid.org/0000-0002-2412-0459>

Submitted on February 1, 2022; resubmitted on June 15, 2022; editorial decision on June 22, 2022

STUDY QUESTION: Do children whose mothers have polycystic ovary syndrome (PCOS) have an increased risk of morbidity?

SUMMARY ANSWER: Maternal PCOS is associated with an increased risk of infection, allergy and other childhood morbidity.

WHAT IS KNOWN ALREADY: PCOS is associated with higher rates of gestational diabetes, pre-eclampsia and preterm delivery, but the long-term impact on child health is poorly understood.

STUDY DESIGN, SIZE, DURATION: We conducted a retrospective longitudinal cohort study of 1 038 375 children in Quebec between 2006 and 2020.

PARTICIPANTS/MATERIALS, SETTING, METHODS: We included 7160 children whose mothers had PCOS and 1 031 215 unexposed children. Outcomes included child hospitalization for infectious, allergic, malignant and other diseases before 13 years of age. We estimated hazard ratios (HRs) and 95% CI for the association of PCOS with childhood morbidity in adjusted Cox proportional hazards regression models.

MAIN RESULTS AND THE ROLE OF CHANCE: Children exposed to PCOS were hospitalized at a rate of 68.9 (95% CI 66.2–71.8) per 1000 person-years, whereas unexposed children were hospitalized at a rate of 45.3 (95% CI 45.1–45.5) per 1000 person-years. Compared with no exposure, maternal PCOS was associated with 1.32 times the risk of any childhood hospitalization (95% CI 1.26–1.40), 1.31 times the risk of infectious disease hospitalization (95% CI 1.25–1.38) and 1.47 times the risk of allergy-related hospitalization (95% CI 1.31–1.66). Risk of hospitalization was also elevated for childhood metabolic (HR 1.59, 95% CI 1.16–2.18), gastrointestinal (HR 1.72, 95% CI 1.53–1.92), central nervous system (HR 1.74, 95% CI 1.46–2.07) and otologic disorders (HR 1.34, 95% CI 1.26–1.43). Subgroup analyses suggested that there was little difference in the association of PCOS with hospitalization among boys (HR 1.31, 95% CI 1.24–1.39) and girls (HR 1.34, 95% CI 1.26–1.43).

LIMITATIONS, REASONS FOR CAUTION: We analyzed severe childhood morbidity requiring hospitalization, not mild diseases treated in ambulatory clinics. We lacked data on ethnicity, education and physical activity, and cannot rule out residual confounding.

WIDER IMPLICATIONS OF THE FINDINGS: Our findings suggest that maternal PCOS is associated with an increased risk of childhood morbidity.

STUDY FUNDING/COMPETING INTEREST(S): This study was supported by grant PJT-162300 from the Canadian Institutes of Health Research. N.A. acknowledges a career award from the Fonds de recherche du Québec-Santé (296785). The authors declare no competing interests.

TRIAL REGISTRATION NUMBER: N/A.

Key words: allergic diseases / cardiovascular diseases / central nervous system diseases / childhood morbidity / epidemiology / infectious diseases / metabolic diseases / neoplasms / polycystic ovary syndrome / PCOS

Introduction

Polycystic ovary syndrome (PCOS) is a common reproductive disorder, characterized by ovarian dysfunction, hyperandrogenism, polycystic ovary morphology and metabolic complications (Witchel *et al.*, 2019). PCOS affects up to 10% of women of reproductive age (Bozdag *et al.*, 2016). Women with PCOS are at risk of obesity, type 2 diabetes and cardiovascular disease, and a number of studies suggest that there may be associations with adverse pregnancy outcomes such as gestational diabetes, pre-eclampsia and preterm birth (Palomba *et al.*, 2015; McDonnell and Hart, 2017). Although an impact on birth outcomes has been documented, the long-term health of children whose mothers have PCOS has received limited attention.

Owing to elevated circulating androgen levels, metabolic dysfunction and the potential for a suboptimal intrauterine environment in women with PCOS, researchers have raised concern over the somatic and neurodevelopmental health of children who are exposed to these conditions *in utero* (Palomba *et al.*, 2015; Bell *et al.*, 2018a). Hyperandrogenism and insulin resistance may affect fetal neuroendocrine and immune programming, possibly impacting the long-term health of offspring (Cardoso and Padmanabhan, 2019). Studies have found that maternal PCOS is associated with faster catch-up growth and greater BMI in childhood (Recabarren *et al.*, 2008; Finnbogadóttir *et al.*, 2017). Children of women with PCOS are more likely to have insulin resistance, abnormal lipid profiles and diabetes (Wilde *et al.*, 2018; Gunning *et al.*, 2020; Chen *et al.*, 2021), as well as attention deficit disorders (Kosidou *et al.*, 2017), autism spectrum disorder (Kosidou *et al.*, 2016; Cherskov *et al.*, 2018; Chen *et al.*, 2020) and developmental delay (Bell *et al.*, 2018b). We assessed the association between maternal PCOS and risk of child morbidity requiring hospitalization before 13 years of age.

Materials and methods

Study design and population

We performed a longitudinal cohort study of children born between 1 April 2006 and 31 March 2019 in Quebec, Canada. We used data from the Maintenance and Use of Data for the Study of Hospital Clientele repository, which contains discharge records for all inpatient hospitalizations in the province (Auger *et al.*, 2021). Diagnostic variables in the repository are coded by professional archivists who apply algorithms to verify data quality. The dataset is validated and previous studies have found high sensitivity and specificity for child outcomes (Brisson *et al.*, 2003; Nakhla *et al.*, 2019). Children are matched with their mothers. We used unique identification numbers to follow the children from birth until 31 March 2020 to identify morbidities that led to admissions before 13 years of age.

Exposure

The main exposure measure was maternal PCOS. We identified PCOS using *International Classification of Disease* codes (9th version before 31 March 2006; 10th version beginning 1 April 2006) (Supplementary Table S1). We identified women who had a diagnosis of PCOS in their prenatal chart or were hospitalized for the treatment

of PCOS either before or after pregnancy. The comparison group included children whose mothers did not have PCOS.

Outcomes

The main outcome measure comprised childhood hospitalizations up to 13 years of age. There were three primary outcomes, categorized as infectious, allergic and malignant diseases. Infectious diseases included upper respiratory tract, bronchitis, bronchiolitis, pneumonia, infectious enteritis, nephritis, septicemia, otitis media, eye infection, meningitis and other infectious conditions. Allergic diseases included allergic asthma, anaphylaxis, atopic dermatitis, urticaria and other allergic disorders. Malignant diseases included leukemia, lymphoma, neuroblastoma, retinoblastoma, sarcoma and other solid tumors. We used *International Classification of Diseases-10* codes to classify all outcomes. We additionally used morphology and topography codes in the *International Classification of Diseases for Oncology-3* for childhood cancer (Steliarova-Foucher *et al.*, 2005).

Secondary outcomes included morbidities categorized by system: respiratory (respiratory infections, asthma, other respiratory disorders), cardiovascular (arrhythmia, cardiomyopathy, heart valve disorder, hypertension, heart failure, pulmonary vascular disease, stroke), metabolic (type 1 and 2 diabetes, obesity, metabolic syndrome, hypertension, dyslipidemia), gastrointestinal (esophageal, gastric and duodenal disorders, enteritis and colitis, other), urinary (nephritis, pyonephrosis, renal tubulointerstitial disorders, renal failure, cystitis, urethritis, urethral syndrome), genital (hydrocele, spermatocele), musculoskeletal (inflammatory arthropathies, kyphoscoliosis), central nervous system (cerebral palsy, epilepsy, hydrocephalus, other), ophthalmologic (eyelid/lacrimal/orbit, conjunctival, retina/choroid disorders, lacrimal stenosis, ophthalmitis, strabismus, visual disturbances, blindness, other), otologic (suppurative and nonsuppurative otitis media, otalgia, otorrhoea, otorhagia), and mental and behavioral disorders.

Covariates

We adjusted for maternal characteristics, including age (<30, 30–34, ≥35 years), parity (0, 1, ≥2), ART, maternal comorbidity (hypertension, type 1 and 2 diabetes, obesity, dyslipidemia, maternal mental disorders, allergy and asthma), substance use disorders (tobacco, alcohol, drugs), socioeconomic deprivation (yes, no, unspecified) and year of birth (2006–2010, 2011–2015, 2016–2019). Data for ART were missing for 2006 and 2007, which we placed in a separate category (Wei *et al.*, 2021). Socioeconomic deprivation was determined from Canada census data and defined as the most deprived fifth of neighborhoods for mean income, employment rate and education (Pampalon *et al.*, 2012).

Statistical analysis

We calculated hospitalization rates per 1000 person-years and the cumulative incidence at 13 years of age. We estimated hazard ratios (HRs) with 95% CI for the association of maternal PCOS with childhood hospitalization using Cox proportional hazards regression. Models were adjusted for maternal age, parity, ART, maternal comorbidity, substance use disorders, socioeconomic deprivation and year of birth. We defined the follow-up time as the number of days between birth and the first hospitalization for each outcome, or the study end

on 31 March 2020. We used robust sandwich estimators to account for children with the same mother. Children who were never hospitalized or died before the end of the study were censored. As prenatal exposure to hyperandrogenism may influence boys and girls differently, we carried out subgroup analyses stratified by child sex. We also examined if the association of PCOS with hospitalization varied during infancy (<2 years), early childhood (2 to 4 years) and later childhood (5 to 13 years).

In sensitivity analyses, we examined models that were not adjusted for maternal comorbidity, and excluded children who were conceived by ART, were multiple births, had mothers with comorbidity, or were born preterm, to rule out an effect of these factors. Analyses were performed in SAS v9.4 (SAS Institute Inc., Cary, NC, USA).

Ethics approval

We obtained an ethics waiver from the institutional review board of the University of Montreal Hospital Centre, as data from hospital discharge abstracts are anonymized.

Results

Population characteristics

We followed 1 038 375 children from birth up to 13 years of age, for a total of 7719 940 person-years under study (Table I). The cohort included 7160 children whose mothers had PCOS and 1 031 215 children who were unexposed. Mothers with PCOS were more likely to be older (≥ 30 years: 60.7% versus 51.8%), nulliparous (55.4% versus 49.0%) and have comorbidities including obesity, type 1 and 2 diabetes, hypertension and dyslipidemia (24.8% versus 8.5%) compared with no PCOS. Mothers with PCOS were more likely to have used ART than mothers without PCOS (14.7% versus 1.8%). The percentage of substance use disorders and socioeconomic deprivation was comparable among mothers with and without PCOS.

Childhood hospitalization rates

A total of 275 354 children were hospitalized during follow-up, including 2314 (0.8%) children whose mothers had PCOS (Supplementary Table SII). Hospitalization rates were higher for children exposed to PCOS (68.9 per 1000 person-years, 95% CI 66.2–71.8) than unexposed children (45.3 per 1000 person-years, 95% CI 45.1–45.5). Children exposed to PCOS had a higher cumulative incidence of hospitalization at 13 years (39.0 per 100) compared with unexposed children (31.8 per 100).

Association of PCOS with childhood hospitalization

In adjusted Cox models, PCOS was associated with 1.32 times the risk of any childhood hospitalization compared with no PCOS (95% CI 1.26–1.40) (Table II). PCOS was associated with 1.31 times the risk of infection hospitalization (95% CI 1.25–1.38) and 1.47 times the risk of allergy hospitalization (95% CI 1.31–1.66), but the risk of cancer was not elevated (HR 1.17, 95% CI 0.67–2.05). PCOS was associated with 1.32 times the risk of respiratory (95% CI 1.23–1.41), 1.59 times the

Table I Characteristics of children exposed to maternal PCOS.

	PCOS n = 7160	No PCOS n = 1 031 215
Maternal age, years ^a		
<30	2813 (39.3)	497 217 (48.2)
30–34	2783 (38.9)	347 870 (33.7)
≥ 35	1564 (21.8)	186 128 (18.1)
Parity		
0	3965 (55.4)	505 610 (49.0)
1	2285 (31.9)	357 935 (34.7)
≥ 2	910 (12.7)	167 670 (16.3)
ART		
Yes	1056 (14.7)	18 418 (1.8)
No	5152 (72.0)	784 144 (76.0)
Maternal comorbidity ^a		
Yes	1776 (24.8)	87 945 (8.5)
No	5384 (75.2)	950 430 (91.5)
Substance use disorder ^b		
Yes	112 (1.6)	20 107 (2.0)
No	7048 (98.4)	1 011 108 (98.0)
Socioeconomic deprivation		
Yes	1285 (18.0)	207 057 (20.1)
No	5875 (82.0)	824 158 (79.9)
Year of birth		
2006–2010	1845 (25.8)	387 059 (37.5)
2011–2015	3050 (42.6)	403 005 (39.1)
2016–2019	2265 (31.6)	241 151 (23.4)

^aHypertension, type 1 and 2 diabetes, obesity, dyslipidemia, mental disorders, allergy and asthma.

^bTobacco, alcohol and drug use disorders.

PCOS, polycystic ovary syndrome.

risk of metabolic (95% CI 1.16–2.18), 1.72 times the risk of gastrointestinal (95% CI 1.53–1.92), 1.74 times the risk of central nervous system (95% CI 1.46–2.07), 1.46 times the risk of ophthalmologic (95% CI 1.27–1.67) and 1.34 times the risk of otologic hospitalization (95% CI 1.26–1.43). PCOS was also associated with hospitalization for mental and behavioral disorders (HR 1.68, 95% CI 1.42–1.99). PCOS was not associated with cardiovascular, malignancy or musculoskeletal hospitalization.

Compared with no exposure, children whose mothers had PCOS were at risk of hospitalization for several diseases (Supplementary Table SIII). PCOS was associated with 1.30 times the risk of otitis media (95% CI 1.22–1.38), 1.21 times the risk of pneumonia (95% CI 1.08–1.34), 1.43 times the risk of gastroenteritis (95% CI 1.25–1.64), 1.54 times the risk of asthma (95% CI 1.36–1.76) and 1.71 times the risk of metabolic syndrome hospitalization (95% CI 1.27–2.30).

Association according to child sex

Subgroup analyses stratified by child sex suggested that there was little difference in the association of PCOS with hospitalization among boys

Table II Association of maternal PCOS with childhood hospitalization.

	No. children		Hospitalization rate per 1000 person-years (95% CI)		Hazard ratio (95% CI)	
	PCOS	No PCOS	PCOS	No PCOS	Unadjusted	Adjusted ^a
Type of hospitalization						
Any	2314	273 040	68.9 (66.2–71.8)	45.3 (45.1–45.5)	1.35 (1.30–1.42)	1.32 (1.26–1.40)
Infection	2051	240 220	59.2 (56.7–61.8)	38.9 (38.7–39.0)	1.34 (1.28–1.41)	1.31 (1.25–1.38)
Allergy	289	28 727	6.5 (5.8–7.3)	3.8 (3.8–3.9)	1.57 (1.40–1.77)	1.47 (1.31–1.66)
Cancer	12	1659	0.3 (0.1–0.5)	0.2 (0.2–0.2)	1.15 (0.65–2.03)	1.17 (0.67–2.05)
Physiological system						
Respiratory	1070	122 443	27.0 (25.4–28.6)	17.8 (17.7–17.9)	1.33 (1.24–1.42)	1.32 (1.23–1.41)
Cardiovascular	50	5215	1.1 (0.8–1.4)	0.7 (0.7–0.7)	1.48 (1.11–1.96)	1.31 (0.99–1.74)
Metabolic	40	3921	0.9 (0.6–1.2)	0.5 (0.5–0.5)	1.68 (1.23–2.29)	1.59 (1.16–2.18)
Gastrointestinal	333	29 885	7.6 (6.8–8.5)	4.0 (4.0–4.1)	1.78 (1.59–1.99)	1.72 (1.53–1.92)
Urinary	172	18 333	3.8 (3.3–4.5)	2.4 (2.4–2.5)	1.40 (1.20–1.63)	1.43 (1.23–1.66)
Genital	38	4194	1.6 (1.2–2.2)	1.1 (1.0–1.1)	1.40 (1.02–1.92)	1.36 (0.99–1.87)
Musculoskeletal	11	2024	0.2 (0.1–0.4)	0.3 (0.3–0.3)	0.89 (0.49–1.60)	0.85 (0.47–1.53)
Central nervous system	141	11 407	3.1 (2.6–3.7)	1.5 (1.5–1.5)	1.97 (1.66–2.34)	1.74 (1.46–2.07)
Ophthalmologic	222	22 929	5.0 (4.4–5.7)	3.0 (3.0–3.1)	1.52 (1.33–1.73)	1.46 (1.27–1.67)
Otologic	1160	128 177	29.3 (27.7–31.1)	18.6 (18.5–18.7)	1.40 (1.32–1.50)	1.34 (1.26–1.43)
Mental and behavioral	145	13 196	3.2 (2.7–3.8)	1.7 (1.7–1.8)	1.87 (1.58–2.21)	1.68 (1.42–1.99)

^aHazard ratio for PCOS relative to no PCOS, adjusted for maternal age, parity, ART, maternal comorbidity, substance use disorder, socioeconomic deprivation and year of birth. PCOS, polycystic ovary syndrome.

(HR 1.31, 95% CI 1.24–1.39) and girls (HR 1.34, 95% CI 1.26–1.43) (Table III). PCOS was associated with infection, allergy, respiratory, gastrointestinal, urinary, central nervous system, ophthalmologic, and mental and behavioral hospitalization among both boys and girls. However, PCOS was associated with metabolic disorders in boys (HR 1.76, 95% CI 1.19–2.62), but not girls (HR 1.37, 95% CI 0.82–2.28).

Association according to child age

The association between PCOS and hospitalization was slightly stronger earlier in childhood (Table IV). Compared with no exposure, PCOS was associated with 1.36 times the risk of any hospitalization before 2 years (95% CI 1.29–1.43), 1.24 times the risk at 2 to 4 years (95% CI 1.13–1.35) and 1.28 times the risk at 5 to 13 years (95% CI 1.10–1.49). Associations with allergy, respiratory, gastrointestinal, central nervous system, ophthalmologic, and mental and behavioral hospitalization persisted after 5 years. Associations with infection and otologic hospitalization were, however, attenuated after 5 years of age.

Sensitivity analyses

In models not adjusted for maternal comorbidity, maternal PCOS was slightly more strongly associated with adverse offspring outcomes (Supplementary Table SIV). Excluding children who conceived with ART, were multiple births, or were born preterm did not affect the results. However, excluding mothers with comorbidity resulted in an elevated risk of child mental and behavioral disorders (HR 1.92, 95% CI 1.58–2.33).

Table III Association between maternal PCOS and childhood morbidity stratified by child sex.

	Hazard ratio ^a (95% CI)	
	Boys (n = 532 876)	Girls (n = 505 499)
Type of hospitalization		
Any	1.31 (1.24–1.39)	1.34 (1.26–1.43)
Infection	1.31 (1.23–1.38)	1.32 (1.24–1.41)
Allergy	1.52 (1.32–1.76)	1.38 (1.13–1.68)
Cancer	0.91 (0.38–2.20)	1.46 (0.69–3.08)
Physiological system		
Respiratory	1.30 (1.20–1.40)	1.34 (1.22–1.48)
Cardiovascular	1.39 (0.97–1.99)	1.21 (0.77–1.88)
Metabolic	1.76 (1.19–2.62)	1.37 (0.82–2.28)
Gastrointestinal	1.74 (1.51–2.01)	1.68 (1.43–1.99)
Urinary	1.57 (1.27–1.93)	1.31 (1.05–1.62)
Genital	1.36 (0.99–1.88)	–
Musculoskeletal	0.46 (0.15–1.42)	1.24 (0.62–2.49)
Central nervous system	1.70 (1.36–2.12)	1.79 (1.39–2.32)
Ophthalmologic	1.49 (1.25–1.78)	1.42 (1.16–1.73)
Otologic	1.31 (1.22–1.42)	1.37 (1.25–1.50)
Mental and behavioral	1.73 (1.41–2.12)	1.58 (1.20–2.10)

^aHazard ratio for PCOS relative to no exposure, adjusted for maternal age, parity, ART, maternal comorbidity, substance use disorder, socioeconomic deprivation and year of birth. PCOS, polycystic ovary syndrome.

Table IV Association of maternal PCOS with hospitalization according to child age.

	Hazard ratio ^a (95% CI)		
	<2 years	2–4 years	≥5 years
Type of hospitalization			
Any	1.36 (1.29–1.43)	1.24 (1.13–1.35)	1.28 (1.10–1.49)
Infection	1.34 (1.27–1.42)	1.27 (1.15–1.39)	1.14 (0.93–1.38)
Allergy	1.54 (1.31–1.82)	1.40 (1.15–1.70)	1.40 (1.02–1.93)
Cancer	1.49 (0.67–3.32)	1.52 (0.69–3.36)	0.00 (0.00–0.00)
Physiological system			
Respiratory	1.30 (1.22–1.40)	1.30 (1.13–1.49)	1.37 (1.06–1.76)
Cardiovascular	1.37 (0.98–1.91)	1.26 (0.62–2.54)	1.05 (0.43–2.53)
Metabolic	1.45 (0.88–2.38)	1.77 (1.00–3.15)	1.66 (0.94–2.93)
Gastrointestinal	1.87 (1.63–2.14)	1.44 (1.06–1.97)	1.39 (1.05–1.83)
Urinary	1.42 (1.20–1.68)	1.45 (0.93–2.25)	1.45 (0.77–2.70)
Genital	1.29 (0.79–2.11)	1.35 (0.82–2.21)	1.63 (0.73–3.67)
Musculoskeletal	1.09 (0.45–2.66)	0.58 (0.19–1.79)	0.92 (0.30–2.87)
Central nervous system	1.73 (1.30–2.30)	1.56 (1.20–2.03)	2.20 (1.55–3.12)
Ophthalmologic	1.49 (1.23–1.80)	1.34 (1.05–1.70)	1.59 (1.15–2.20)
Otologic	1.37 (1.26–1.48)	1.30 (1.17–1.45)	1.16 (0.89–1.50)
Mental and behavioral	1.81 (1.38–2.38)	1.90 (1.26–2.87)	1.52 (1.13–2.04)

^aHazard ratio for PCOS relative to no PCOS, adjusted for maternal age, parity, ART, maternal comorbidity, substance use disorder, socioeconomic deprivation and year of birth. There were 1 038 375 children at risk before 2 years, 791 129 children at risk between 2 and 4 years and 533 831 children at risk at ≥5 years. PCOS, polycystic ovary syndrome.

Discussion

In this study of 1 038 375 children followed from birth to 13 years of age, children exposed to maternal PCOS had a higher risk of hospitalization compared with unexposed children after adjusting for maternal comorbidities and other confounders. PCOS was associated with elevated risks of hospitalization for infectious, allergic and other disorders, but not malignant diseases. Risks of specific disorders, including otitis media, pneumonia, asthma, nephritis and metabolic syndrome, were all elevated. The associations were stronger earlier in childhood but persisted after 5 years of age for allergy, gastrointestinal, central nervous system, and mental and behavioral disorders. There was little evidence of a difference between boys and girls. Moreover, the associations were not explained by ART, multiple birth, maternal comorbidity or preterm birth. Overall, the findings suggest that maternal PCOS may have a negative impact on offspring development, enough to lead to a measurable increase in the risk of childhood hospitalization.

Few studies have investigated the long-term impact of maternal PCOS on offspring outcomes. Our findings suggest that children exposed to maternal PCOS may be at risk of infectious and allergic hospitalization. In the only other cohort study of infectious outcomes, maternal PCOS was associated with an increase in the number of hospitalizations for upper and lower respiratory tract infections and asthma among 38 028 Australian children (Doherty *et al.*, 2015). A cross-sectional study from the Netherlands found that maternal

PCOS was associated with elevated inflammatory cytokines in offspring, suggesting a propensity toward chronic inflammation and risk of infection (Daan *et al.*, 2016).

An emerging body of evidence suggests that maternal PCOS may be linked with the cardiometabolic profiles of offspring. A recent systematic review and meta-analysis reported that children of women with PCOS are more likely to have insulin resistance and hypertriglyceridemia (Gunning *et al.*, 2020). Studies have found that children exposed to PCOS have higher concentrations of triglycerides and low-density lipoprotein cholesterol, and greater carotid intima-media thickness (Wilde *et al.*, 2018), as well as faster catch-up growth and greater BMI at 3 years of age (Finnbogadóttir *et al.*, 2017). A cohort study of 24 682 children in Finland concluded that children of women with PCOS had an increased risk of obesity and diabetes (Chen *et al.*, 2021). Our results align with much of this body of evidence as we found a consistent association between maternal PCOS and metabolic disorder hospitalization, including metabolic syndrome and type 1 and 2 diabetes.

Recent studies suggest that maternal PCOS may impact offspring neurodevelopment (Kosidou *et al.*, 2016, 2017; Cherskov *et al.*, 2018; Bell *et al.*, 2018b; Chen *et al.*, 2020). Children exposed to PCOS appear to have increased risks of attention deficit hyperactivity disorder (Kosidou *et al.*, 2017; Chen *et al.*, 2020), autism spectrum disorder (Kosidou *et al.*, 2016; Cherskov *et al.*, 2018; Chen *et al.*, 2020) and intellectual disability (Chen *et al.*, 2020) compared with unexposed children. A cohort study of 5388 children in the USA found that exposure

to maternal PCOS was associated with a higher risk of developmental delay before 3 years of age (Bell *et al.*, 2018b). Another cohort study suggested that PCOS was associated with neuropsychiatric disorders after accounting for genetic and environmental confounders (Cesta *et al.*, 2020). Our findings accord with previous studies that suggest that exposure to maternal PCOS increases the risk of central nervous system, and mental and behavioral, disorders in children.

The pathways linking PCOS with childhood morbidity have yet to be established. Circulating androgen levels and insulin resistance, the two hallmarks of PCOS, have been linked with oxidative stress, inflammation, endothelial dysfunction and placental abnormalities in pregnant women (Murri *et al.*, 2013; Koster *et al.*, 2015; Rudnicka *et al.*, 2021). A recent systematic review found that women with PCOS had greater concentrations of oxidative biomarkers, including homocysteine (Murri *et al.*, 2013). Hyperhomocysteinemia is associated with fetal growth restriction and low birthweight (Yajnik *et al.*, 2014). Maternal PCOS may also impair immune function and lead to low-grade systemic inflammation in the child (Daan *et al.*, 2016; Rudnicka *et al.*, 2021).

Women with PCOS may have placental abnormalities, including chorioamnionitis, funisitis, villitis, thrombosis, infarction and impaired placental maturation, all of which are associated with a hypoxic state and a suboptimal intrauterine environment (Koster *et al.*, 2015). Studies have consistently demonstrated that the intrauterine environment can influence fetal programming during critical developmental stages (Kwon and Kim, 2017). Suboptimal intrauterine environments owing to hyperandrogenism and metabolic dysfunction may affect fetal neuroendocrine and immune programming and metabolism, and impact health outcomes in childhood (Vankay *et al.*, 2019). In addition, intrauterine PCOS exposure may affect DNA methylation patterns in the promoter regions of metabolic genes (Echiburú *et al.*, 2020). Genome-wide studies have identified candidate genes related to the etiology of PCOS (Al-Khaduri *et al.*, 2020). In addition, observational studies have found evidence of transgenerational effects in offspring (Risal *et al.*, 2019).

Women with PCOS may be more likely to have comorbidities such as asthma, obesity and diabetes. Some studies suggest that maternal obesity and diabetes increase the risk of adverse offspring outcomes (Godfrey *et al.*, 2017; Yu *et al.*, 2019). Maternal asthma is associated with offspring asthma and allergic disorders (Morten *et al.*, 2018; Sly, 2019). Although PCOS remained associated with childhood hospitalization after adjustment for maternal comorbidity in our data, it is possible that other unmeasured maternal morbidities contribute to our findings or that morbidity is a mediator.

This study has strengths. We used a longitudinal population-based cohort with a large sample size that allowed us to investigate a range of childhood disorders while controlling for a number of potential confounders. We followed the children over more than a decade with little possibility of recall or attrition bias. There are nevertheless limitations. We used a register-based cohort in which we captured severe cases of PCOS that required medical treatment but could not identify women with mild PCOS who were never diagnosed. We analyzed severe childhood morbidity requiring hospitalization, not mild diseases treated in ambulatory clinics. Exposures and outcomes in administrative hospital data may be misclassified, which may attenuate the associations without affecting the overall interpretations. We did not have data on genetic variants or phenotypes of PCOS. We lacked data on ethnicity, education, maternal pre-pregnancy BMI, gestational

weight gain and physical activity, and cannot rule out residual confounding. We had no information on paternal age or medical conditions, and medications such as metformin. *E*-values suggested that a confounder would have to be associated with two times the risk of PCOS and child hospitalization to explain away the associations we observed (Supplementary Table SV) (VanderWeele and Ding, 2017). We cannot exclude the possibility of detection bias owing to a greater number of physician visits in women with PCOS.

In summary, we found that children exposed to maternal PCOS have a greater risk of hospitalization for infection, allergy and other childhood morbidity before 13 years of age. The association between PCOS and childhood morbidity is stronger earlier in childhood but persists after 5 years of age. The association is also independent of exposures such as advanced maternal age or ART. Further research is needed to determine if effective management of maternal PCOS may reduce childhood morbidity and improve long-term health.

Supplementary data

Supplementary data are available at *Human Reproduction* online.

Data availability

Code book and analytic code may be requested from the authors. Data described in the manuscript can be requested from the Quebec Ministry of Health and Social Services following standardized access procedures.

Authors' roles

S.Q.W. and N.A. conceived the study. S.Q.W., M.B.-B. and N.A. designed the study. S.Q.W. analyzed the data. S.Q.W., M.B.-B. and N.A. interpreted the data. S.Q.W. wrote the draft, and M.B.-B. and N.A. revised the manuscript. All authors approved the final version.

Funding

This work was supported by grant PJT-162300 from the Canadian Institutes of Health Research. N.A. acknowledges a career award from the Fonds de recherche du Québec-Santé (296785).

Conflict of interest

None declared.

References

- Al-Khaduri M, Kindi FAA, Tamimi Y, Nomani AH, Al-Farsi YM. Identification of novel mutations in candidate genes associated with polycystic ovary syndrome (PCOS) in women with arab ethnicity. *Fertil Steril* 2020;114:e547–e548.
- Auger N, Soullane S, Luu TM, Lee GE, Wei SQ, Quach C. Association of cesarean delivery with childhood hospitalization

for infections before 13 years of age. *J Pediatr* 2021; **231**: 178–184.e2.

Bell GA, Sundaram R, Mumford SL, Park H, Broadney M, Mills JL, Bell EM, Yeung EH. Maternal polycystic ovarian syndrome and offspring growth: the Upstate KIDS Study. *J Epidemiol Community Health* 2018a; **72**: 852–855.

Bell GA, Sundaram R, Mumford SL, Park H, Mills J, Bell EM, Broadney M, Yeung EH. Maternal polycystic ovarian syndrome and early offspring development. *Hum Reprod* 2018b; **33**: 1307–1315.

Bozdag G, Mumusoglu S, Zengin D, Karabulut E, Yildiz BO. The prevalence and phenotypic features of polycystic ovary syndrome: a systematic review and meta-analysis. *Hum Reprod* 2016; **31**: 2841–2855.

Brisson J, Major D, Pelletier É. Évaluation de l'exhaustivité du Fichier des tumeurs du Québec. Québec City, Canada: Institut national de santé publique du Québec, 2003. <https://www.inspq.qc.ca/pdf/publications/217-RapportExhaustiviteRegistreCancers.pdf>

Cardoso RC, Padmanabhan V. Developmental programming of PCOS traits: insights from the sheep. *Med Sci* 2019; **7**: 79.

Cesta CE, Öberg AS, Ibrahimson A, Yusuf I, Larsson H, Almqvist C, D'Onofrio BM, Bulik CM, Fernández de la Cruz L, Mataix-Cols D et al. Maternal polycystic ovary syndrome and risk of neuropsychiatric disorders in offspring: prenatal androgen exposure or genetic confounding? *Psychol Med* 2020; **50**: 616–624.

Chen X, Koivuaho E, Piltonen TT, Gissler M, Lavebratt C. Association of maternal polycystic ovary syndrome or anovulatory infertility with obesity and diabetes in offspring: a population-based cohort study. *Hum Reprod* 2021; **36**: 2345–2357.

Chen X, Kong L, Piltonen TT, Gissler M, Lavebratt C. Association of polycystic ovary syndrome or anovulatory infertility with offspring psychiatric and mild neurodevelopmental disorders: a Finnish population-based cohort study. *Hum Reprod* 2020; **35**: 2336–2347.

Cherskov A, Pohl A, Allison C, Zhang H, Payne RA, Baron-Cohen S. Polycystic ovary syndrome and autism: a test of the prenatal sex steroid theory. *Transl Psychiatry* 2018; **8**: 136.

Daan NMP, Koster MPH, de Wilde MA, Dalmeijer GW, Evelein AMV, Fauser BCJM, de Jager W. Biomarker profiles in women with PCOS and PCOS offspring: a pilot study. *PLoS One* 2016; **11**: e0165033.

Doherty DA, Newnham JP, Bower C, Hart R. Implications of polycystic ovary syndrome for pregnancy and for the health of offspring. *Obstet Gynecol* 2015; **125**: 1397–1406.

Echiburú B, Milagro F, Crisosto N, Pérez-Bravo F, Flores C, Arpón A, Salas-Pérez F, Recabarren SE, Sir-Petermann T, Maliqueo M. DNA methylation in promoter regions of genes involved in the reproductive and metabolic function of children born to women with PCOS. *Epigenetics* 2020; **15**: 1178–1194.

Finnbogadóttir SK, Glintborg D, Jensen TK, Kyhl HB, Nohr EA, Andersen M. Insulin resistance in pregnant women with and without polycystic ovary syndrome, and measures of body composition in offspring at birth and three years of age. *Acta Obstet Gynecol Scand* 2017; **96**: 1307–1314.

Godfrey KM, Reynolds RM, Prescott SL, Nyirenda M, Jaddoe VWW, Eriksson JG, Broekman BFP. Influence of maternal obesity on the long-term health of offspring. *Lancet Diabetes Endocrinol* 2017; **5**: 53–64.

Gunning MN, Sir Petermann T, Crisosto N, van Rijn BB, de Wilde MA, Christ JP, Uiterwaal CSPM, de Jager W, Eijkemans MJC, Kunselman AR et al. Cardiometabolic health in offspring of women with PCOS compared to healthy controls: a systematic review and individual participant data meta-analysis. *Hum Reprod Update* 2020; **26**: 104–118.

Kosidou K, Dalman C, Widman L, Arver S, Lee BK, Magnusson C, Gardner RM. Maternal polycystic ovary syndrome and the risk of autism spectrum disorders in the offspring: a population-based nationwide study in Sweden. *Mol Psychiatry* 2016; **21**: 1441–1448.

Kosidou K, Dalman C, Widman L, Arver S, Lee BK, Magnusson C, Gardner RM. Maternal polycystic ovary syndrome and risk for attention-deficit/hyperactivity disorder in the offspring. *Biol Psychiatry* 2017; **82**: 651–659.

Koster MPH, Wilde MA, de Veltman-Verhulst SM, Houben ML, Nikkels PGJ, Rijn BB, van Fauser, BCJM. Placental characteristics in women with polycystic ovary syndrome. *Hum Reprod* 2015; **30**: 2829–2837.

Kwon EJ, Kim YJ. What is fetal programming?: a lifetime health is under the control of in utero health. *Obstet Gynecol Sci* 2017; **60**: 506–519.

McDonnell R, Hart RJ. Pregnancy-related outcomes for women with polycystic ovary syndrome. *Womens Health (Lond)* 2017; **13**: 89–97.

Morten M, Collison A, Murphy VE, Barker D, Oldmeadow C, Attia J, Meredith J, Powell H, Robinson PD, Sly PD et al. Managing Asthma in Pregnancy (MAP) trial: FENO levels and childhood asthma. *J Allergy Clin Immunol* 2018; **142**: 1765–1772.e4.

Murri M, Luque-Ramírez M, Insenser M, Ojeda-Ojeda M, Escobar-Morreale HF. Circulating markers of oxidative stress and polycystic ovary syndrome (PCOS): a systematic review and meta-analysis. *Hum Reprod Update* 2013; **19**: 268–288.

Nakhla M, Simard M, Dube M, Larocque I, Plante C, Legault L, Huot C, Gagné N, Gagné J, Wafa S et al. Identifying pediatric diabetes cases from health administrative data: a population-based validation study in Quebec. *Clin Epidemiol* 2019; **11**: 833–843.

Palomba S, Wilde MA, de Falbo A, Koster MPH, La Sala GB, Fauser BCJM. Pregnancy complications in women with polycystic ovary syndrome. *Hum Reprod Update* 2015; **21**: 575–592.

Pampalon R, Hamel D, Gamache P, Philibert MD, Raymond G, Simpson A. An area-based material and social deprivation index for public health in Québec and Canada. *Can J Public Health* 2012; **103**: S17–S22.

Recabarren SE, Smith R, Rios R, Maliqueo M, Echiburú B, Codner E, Cassorla F, Rojas P, Sir-Petermann T, Sir-Petermann T. Metabolic profile in sons of women with polycystic ovary syndrome. *J Clin Endocrinol Metab* 2008; **93**: 1820–1826.

Risal S, Pei Y, Lu H, Manti M, Fornes R, Pui H-P, Zhao Z, Massart J, Ohlsson C, Lindgren E et al. Prenatal androgen exposure and transgenerational susceptibility to polycystic ovary syndrome. *Nat Med* 2019; **25**: 1894–1904.

Rudnicka E, Suchta K, Grymowicz M, Calik-Ksepka A, Smolarczyk K, Duszewska AM, Smolarczyk R, Meczekalski B. Chronic low grade inflammation in pathogenesis of PCOS. *IJMS* 2021; **22**: 3789.

Sly PD. Maternal asthma, pregnancy complications, and offspring wheeze. Untangling the web. *Am J Respir Crit Care Med* 2019; **199**: 1–2.

Steliarova-Foucher E, Stiller C, Lacour B, Kaatsch P. International classification of childhood cancer, third edition. *Cancer* 2005; **103**: 1457–1467.

VanderWeele TJ, Ding P. Sensitivity analysis in observational research: introducing the E-value. *Ann Intern Med* 2017; **167**: 268–274.

Vankay E, Engen Hanem LG, Abbott DH. Children born to women with polycystic ovary syndrome—short- and long-term impacts on health and development. *Fertil Steril* 2019; **111**: 1065–1075.

Wei SQ, Bilodeau-Bertrand M, Lo E, Auger N. Effect of publicly funded assisted reproductive technology on maternal and infant outcomes: a pre- and post-comparison study. *Hum Reprod* 2021; **36**: 219–228.

Wilde MA, Eising JB, Gunning MN, Koster MPH, Evelein AMV, Dalmeijer GW, Uiterwaal CSPM, Eijkemans MJC, Ent CKV, Meijboom FJ et al. Cardiovascular and metabolic health of 74 children from women previously diagnosed with polycystic ovary syndrome in comparison with a population-based reference cohort. *Reprod Sci* 2018; **25**: 1492–1500.

Witchel SF, Oberfield SE, Peña AS. Polycystic ovary syndrome: pathophysiology, presentation, and treatment with emphasis on adolescent girls. *J Endocr Soc* 2019; **3**: 1545–1573.

Yajnik CS, Chandak GR, Joglekar C, Katre P, Bhat DS, Singh SN, Janipalli CS, Refsum H, Krishnaveni G, Veena S et al. Maternal homocysteine in pregnancy and offspring birthweight: epidemiological associations and Mendelian randomization analysis. *Int J Epidemiol* 2014; **43**: 1487–1497.

Yu Y, Arah OA, Liew Z, Cnattingius S, Olsen J, Sørensen HT, Qin G, Li J. Maternal diabetes during pregnancy and early onset of cardiovascular disease in offspring: population based cohort study with 40 years of follow-up. *BMJ* 2019; **367**: l6398.